Dare Bioscience (DARE) Net Equity Issued and Repurchased (2013 - 2021)

Dare Bioscience (DARE) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $9.3 million in Q4 2021.

• Quarterly Net Equity Issued and Repurchased fell 41.14% year-over-year to $9.3 million in Q4 2021, while the trailing twelve-month figure through Dec 2022 was $45.5 million (down 19.04% YoY) and the FY2025 annual result came in at $20.9 million, up 4514.44% from the prior year.
• Net Equity Issued and Repurchased slipped to $9.3 million in Q4 2021, from $36.2 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $36.2 million in Q3 2021 to a low of $1.0 in Q1 2020.
• A 5-year average of $9.0 million and a median of $7.2 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2018 — Net Equity Issued and Repurchased surged 16190.32% — and 2021, when it slumped 41.14%.
• Tracing DARE's Net Equity Issued and Repurchased over 5 years: stood at $8000.0 in 2017, then jumped by 126150.0% to $10.1 million in 2018, then plunged by 48.99% to $5.2 million in 2019, then jumped by 206.69% to $15.8 million in 2020, then tumbled by 41.14% to $9.3 million in 2021.
• The last three Net Equity Issued and Repurchased figures came in at $9.3 million (Q4 2021), $36.2 million (Q3 2021), and $10.7 million (Q2 2021), per Business Quant data.